Medicines Co's ORBACTIVT FDA Approval Conference Call Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Aug 7 Calls
Today's Calls
Call Details
Medicines Co's ORBACTIVT FDA Approval Conference Call
Thu, Aug 7, 2014, 8:00 am Eastern

Listen to the archived event audio


About Medicines Co (NasdaqGS:MDCO)Other Calls 
The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.


More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Analyst Ratings


Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.